Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) Cardiometabolic risk in patients with primary aldosteronism and autonomous corti...
Journal Information
Vol. 157. Issue 10.
Pages 473-479 (November 2021)
Share
Share
Download PDF
More article options
ePub
Visits
0
Vol. 157. Issue 10.
Pages 473-479 (November 2021)
Original article
Cardiometabolic risk in patients with primary aldosteronism and autonomous cortisol secretion. Case-control study
Riesgo cardiometabólico en pacientes con hiperaldosteronismo primario y secreción autónoma de cortisol. Estudio de casos y controles
Visits
...
Marta Araujo-Castroa,b,
Corresponding author
marta.araujo@salud.madrid.org

Corresponding author.
, Nuria Bengoa Rojanoa, María Fernández Argüesoa, Eider Pascual-Corralesa, Lucía Jiménez Mendiguchíac, Ana M. García Canoc
a Servicio de Endocrinología y Nutrición, Hospital Universitario Ramón y Cajal, Madrid, Spain
b Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
c Servicio de Bioquímica, Hospital Universitario Ramón y Cajal, Madrid, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (1)
Tables (2)
Table 1. Clinical and laboratory differences at diagnosis in patients with primary hyperaldosteronism and autonomous cortisol secretion.
Table 2. Clinical and laboratory differences in patients throughout the follow-up in patients with primary hyperaldosteronism and autonomous cortisol secretion.
Show moreShow less
Abstract
Objective

To analyse the differences in the cardio-metabolic profile of patients with primary aldosteronism (PA) and autonomous cortisol secretion (ACS) matched by age and sex.

Methods

Case-control study; cases of PA without associated ACS and as controls patients with ACS (dexamethasone suppression test ≥1.8 μg/dL in the absence of specific hypercortisolism clinical data), matched by age and sex. Comorbidities of hypertension, diabetes, obesity, dyslipidaemia, chronic kidney failure, and cardiovascular and cerebrovascular events were analysed, as well as their degree of control.

Results

57 patients with PA and 57 with ACS were included. On diagnosis, in addition to a higher prevalence of hypertension in the PA patients (100 vs. 52.7%, p < .0001) and higher systolic blood pressure levels (143.2 (2.5) vs. 135.3 (2.6) mmHg, p = .032) than in the ACS patients, no other differences were detected in the prevalence of other cardio-metabolic comorbidities. Nevertheless, the patients with ACS had higher HbA1c levels (p = .028) than the PA patients.

After a median follow-up of 2.25 years, the patients with PA presented a greater deterioration in kidney function (Average decrease in glomerular filtration rate (MDRD-4) −17.4 (3.0) vs. −2.3 (4.4) mL/min/1.73 m2, p = .005) and lipid profile (Δtriglycerides of 34.5 (15.8) vs. −6.7 (11.3) mg/dL, p = .038) than the ACS patients.

Conclusions

Despite the higher prevalence of hypertension in the patients with PA than in the patients with ACS matched by age and sex, no differences were detected in the prevalence of other cardio-metabolic comorbidities. However, the PA patients showed a greater deterioration in kidney function and lipid profile throughout the follow-up than the ACS patients.

Keywords:
Primary aldosteronism
Autonomous cortisol secretion
Cardio-metabolic profile
High blood pressure
Resumen
Objetivo

Analizar las diferencias en el perfil cardiometabólico de los pacientes con hiperaldosteronismo primario (HAP) y secreción autónoma de cortisol (SAC), emparejados por edad y sexo.

Métodos

Estudio de casos y controles; casos de HAP sin SAC asociada y como controles, pacientes con SAC (test de supresión de dexametasona ≥1.8 μg/dL en ausencia de datos específicos de hipercortisolismo), emparejados por edad y sexo. Se analizaron las comorbilidades HTA, diabetes, obesidad, dislipemia, insuficiencia renal crónica y eventos cardiovasculares y cerebrovasculares, así como su grado de control.

Resultados

Se incluyeron 57 pacientes con HAP y 57 con SAC. Al diagnóstico, aparte de una mayor prevalencia de HTA en los pacientes con HAP (100 vs. 52,7%, p < 0,0001) y niveles más altos de TAS (143,2 [2,5] vs. 135,3 [2,6] mmHg, p = 0,032) que en SAC, no se detectaron diferencias en la prevalencia de otras comorbilidades. No obstante, los pacientes con SAC presentaban cifras más elevadas de HbA1c (p = 0,028).

Tras una mediana de seguimiento de 2,25 años, los pacientes con HAP presentaron un mayor deterioro de la función renal (descenso medio del filtrado glomerular [MDRD-4] −17,4 [3] vs. −2,3 [4,4] mL/min/1,73 m2, p = 0,005) y del perfil lipídico (Δtriglicéridos de 34,5 [15,8] vs. −6,7 [11,3] mg/dL, p = 0,038) que los SAC.

Conclusiones

A pesar la mayor prevalencia de HTA en los pacientes con HAP que con SAC, emparejados por edad y sexo, no se detectaron diferencias en la prevalencia de otras comorbilidades cardiometabólicas. No obstante, los HAP presentaron un mayor deterioro de la función renal y del perfil lipídico a lo largo del seguimiento que el grupo de SAC.

Palabras clave:
Hiperaldosteronismo primario
Secreción autónoma de cortisol
Perfil cardio-metabólico
Hipertensión arterial

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos